Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

The Modernization of Clozapine
Leung, Jonathan G. , Frye, Mark A. , Singh, Balwinder , Cotes, Robert O. , Leung, Jonathan G , Singh, Balwinder , Cotes, Robert O , León, José de , McElroy, Susan L.

Mayo Clinic

Journal of Clinical Psychopharmacology | September 28, 2022 | Volume: 42 | Issue: 6 | Pages: 565-580

10.1097/jcp.0000000000001606 | PMID 36170148 Get It

Abstract Purpose Although clozapine was Food and Drug Administration (FDA) approved more than 3 decades ago, major barriers and gaps in knowledge continue to prevent its effective and safe use. We review modern-day problems encountered with clozapine in the United States (US). Methods Information surrounding current administrative, clinical, research, and technological gaps or barriers related to clozapine use in the US was reviewed. Findings The history of how clozapine became FDA approved likely contributes to gaps in knowledge. The frequency of safety warnings added to the FDA prescribing information may add to fears about clozapine, as evidence by numerous published survey studies. The clozapine Risk Evaluation and Mitigation Strategy (REMS) program has been modified several times in the last decade, causing access and safety issues for patients, which are discussed. Evidence may suggest that the FDA REMS requirements for hematologic monitoring are too cumbersome, and there may be ability to safely loosen requirements. The COVID-19 pandemic brought forth the ability for extended interval monitoring but also greater awareness of the clozapine-inflammation interaction. Newer guidelines published describe considerations in personalizing clozapine titration based on principles of ethnopsychopharmacology. Emerging technologies to support the use of clozapine are not widely available. Implications Clozapine is a unique life-saving drug but it is underused in the US, despite its established efficacy. The 2021 REMS changes led to significant difficulties for providers and patients. We highlight the importance of the clozapine-inflammation interaction, therapeutic drug monitoring, and the ability for individual care based on patient-specific factors. There is an urgent need for advancing technology used for clozapine monitoring, evaluating barriers created by REMS, and establishing consistent practices throughout the US.
Neuroimmune proteins can differentiate between tauopathies
Cherry, Jonathan D. , Baucom, Zach H., Eppich, Kaleb G., Kirsch, Daniel , Dixon, Erin, Crary, John F. , McKee, Ann C. , Tripodis, Yorghos , Bieniek, Kevin F. , Farrell, Kurt , Whitney, Kristen R. , Uretsky, Madeline , Dickson, Dennis W.

Mayo Clinic

No container title available | September 27, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2092813/v1 Get It

AbstractBackgroundTauopathies are a group of neurodegenerative diseases where there is pathologic accumulation of hyperphosphorylated tau protein (ptau). The most common tauopathy is Alzheimer’s disease (AD), but chronic traumatic encephalopathy (CTE), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and argyrophilic grain disease (AGD) are significant health risks as well. Currently, it is unclear what specific molecular factors might drive each distinct disease and represent therapeutic targets. Additionally, there is a lack of biomarkers that can differentiate each disease in life. Recent work has suggested that neuroinflammatory changes might be specific among distinct diseases and offers a novel resource for mechanistic targets and biomarker candidates.MethodsTo better examine each tauopathy, a 71 immune-related protein multiplex ELISA panel was utilized to analyze anterior cingulate grey matter from 127 individuals neuropathologically diagnosed with AD, CTE, PSP, CBD, and AGD. A partial least square regression analysis was carried out to perform unbiased clustering and identify proteins that are distinctly correlated with each tauopathy correcting for age and gender. Receiver operator characteristic and binary logistic regression analyses were then used to examine the ability of each candidate protein to distinguish diseases. Validation in postmortem cerebrospinal fluid (CSF) from 15 AD and 14 CTE cases was performed to determine if candidate proteins could act as possible novel biomarkers.ResultsFive clusters of immune proteins were identified and compared to each tauopathy to determine if clusters were specific to distinct disease. Each cluster was found to correlate with either CTE, AD, PSP, CBD, or AGD. When examining which proteins were the strongest driver of each cluster, it was observed the most distinctive protein for CTE was 6Ckine, AD was FLT3L, and PSP was IL13. Individual proteins that were specific to CBD and AGD were not observed. 6Ckine was observed to be elevated in CTE CSF compared to AD cases (p = 0.02), further validating the use as possible biomarkers.ConclusionsOverall, these results highlight that different neuroinflammatory responses might underlie unique mechanisms in related neurodegenerative pathologies. Additionally, the use of distinct neuroinflammatory signatures could help differentiate between tauopathies and act as novel biomarker candidates.
Management of Periprosthetic Joint Infections After Hemiarthroplasty of the Hip
Bureau, Antoine, Azad, Marisa Ann , Abdelbary, Hesham , Azad, Marisa A, Azad, Marisa , Bourget-Murray, Jonathan , Grammatopoulos, George , Garceau, Simon P.

Mayo Clinic

JBJS Reviews | September 26, 2022 | Volume: 10 | Issue: 9 | Pages: No page available

10.2106/jbjs.rvw.22.00020 | PMID 36155552 Get It

» Periprosthetic joint infection (PJI) following hip hemiarthroplasty (HA) is a devastating complication, incurring immense health-care costs associated with its treatment and placing considerable burden on patients and their families. These patients often require multiple surgical procedures, extended hospitalization, and prolonged antimicrobial therapy. » Notable risk factors include older age, higher American Society of Anesthesiologists (ASA) score, inadequate antibiotic prophylaxis, non-antibiotic-loaded cementation of the femoral implant, longer duration of the surgical procedure, and postoperative drainage and hematoma. » Although the most frequent infecting organisms are gram-positive cocci such as Staphylococcus aureus , there is a higher proportion of patients with gram-negative and polymicrobial infections after hip HA compared with patients who underwent total hip arthroplasty. » Several surgical strategies exist. Regardless of the preferred surgical treatment, successful management of these infections requires a comprehensive surgical debridement focused on eradicating the biofilm followed by appropriate antibiotic therapy. » A multidisciplinary approach led by surgeons familiar with PJI treatment and infectious disease specialists is recommended for all cases of PJI after hip HA to increase the likelihood of treatment success.
Quality Indicators for Capsule Endoscopy and Deep Enteroscopy
Leighton, Jonathan A. , Brock, Andrew, Semrad, Carol E. , Hass, David J., Guda, Nalini M. , Barkin, Jodie A. , Eisen, Glenn M.

Mayo Clinic

American Journal of Gastroenterology | September 26, 2022 | Volume: 117 | Issue: 11 | Pages: 1780-1796

10.14309/ajg.0000000000001903 | PMID 36155365 Get It

INTRODUCTION: Capsule endoscopy (CE) and deep enteroscopy (DE) can be useful for diagnosing and treating suspected small-bowel disease. Guidelines and detailed recommendations exist for the use of CE/DE, but comprehensive quality indicators are lacking. The goal of this task force was to develop quality indicators for appropriate use of CE/DE by using a modified RAND/UCLA Appropriateness Method. METHODS: An expert panel of 7 gastroenterologists with diverse practice experience was assembled to identify quality indicators. A literature review was conducted to develop a list of proposed quality indicators applicable to preprocedure, intraprocedure, and postprocedure periods. The panelists reviewed the literature; identified and modified proposed quality indicators; rated them on the basis of scientific evidence, validity, and necessity; and determined proposed performance targets. Agreement and consensus with the proposed indicators were verified using the RAND/UCLA Appropriateness Method. RESULTS: The voting procedure to prioritize metrics emphasized selecting measures to improve quality and overall patient care. Panelists rated indicators on the perceived appropriateness and necessity for clinical practice. After voting and discussion, 2 quality indicators ranked as inappropriate or uncertain were excluded. Each quality indicator was categorized by measure type, performance target, and summary of evidence. The task force identified 13 quality indicators for CE and DE. DISCUSSION: Comprehensive quality indicators have not existed for CE or DE. The task force identified quality indicators that can be incorporated into clinical practice. The panel also addressed existing knowledge gaps and posed research questions to better inform future research and quality guidelines for these procedures.
Catastrophic acute failure of pelvic fixation in adult spinal deformity requiring revision surgery: a multicenter review of incidence, failure mechanisms, and risk factors
Martin, Christopher T. , Holton, Kenneth J. , Elder, Benjamin D. , Fogelson, Jeremy L. , Mikula, Anthony L. , Kleck, Christopher J. , Calabrese, David W., Ou-Yang, David , Lovecchio, Francis , Hu, Serena S. , Wood, Kirkham B. , Harper, R. A. Kemp , Ananthakrishnan, Dheera , Schell, Adam, Lieberman, Isador H. , Kisinde, Stanley , DeWald, Christopher J., Colman, Matthew W. , Phillips, Frank M. , Gelb, Daniel E. , Bruckner, Jacob J. , Ross, Lindsey , Johnson, J. Patrick , Kim, Terrence T. , Anand, Neel , Plummer, Zach, Park, Paul , Oppenlander, Mark E., Polly, David W. , Polly, David , Burger, Evalina L. , Patel, Vikas V. , Kim, Han Jo , Harper, Robert, Michael, Keith W. , Nolte, Michael Thomas , Cheng, Joseph S. , Plummer, Zachary J., Sembrano, Jonathan N. , Jones, Kristen E.

Mayo Clinic

Journal of Neurosurgery: Spine | September 23, 2022 | Volume: 38 | Issue: 1 | Pages: 98-106

10.3171/2022.6.spine211559 | PMID 36057123 Get It

OBJECTIVE There are few prior reports of acute pelvic instrumentation failure in spinal deformity surgery. The objective of this study was to determine if a previously identified mechanism and rate of pelvic fixation failure were present across multiple institutions, and to determine risk factors for these types of failures. METHODS Thirteen academic medical centers performed a retrospective review of 18 months of consecutive adult spinal fusions extending 3 or more levels, which included new pelvic screws at the time of surgery. Acute pelvic fixation failure was defined as occurring within 6 months of the index surgery and requiring surgical revision. RESULTS Failure occurred in 37 (5%) of 779 cases and consisted of either slippage of the rods or displacement of the set screws from the screw tulip head (17 cases), screw shaft fracture (9 cases), screw loosening (9 cases), and/or resultant kyphotic fracture of the sacrum (6 cases). Revision strategies involved new pelvic fixation and/or multiple rod constructs. Six patients (16%) who underwent revision with fewer than 4 rods to the pelvis sustained a second acute failure, but no secondary failures occurred when at least 4 rods were used. In the univariate analysis, the magnitude of surgical correction was higher in the failure cohort (higher preoperative T1-pelvic angle [T1PA], presence of a 3-column osteotomy; p < 0.05). Uncorrected postoperative deformity increased failure risk (pelvic incidence–lumbar lordosis mismatch > 10°, higher postoperative T1PA; p < 0.05). Use of pelvic screws less than 8.5 mm in diameter also increased the likelihood of failure (p < 0.05). In the multivariate analysis, a larger preoperative global deformity as measured by T1PA was associated with failure, male patients were more likely to experience failure than female patients, and there was a strong association with implant manufacturer (p < 0.05). Anterior column support with an L5–S1 interbody fusion was protective against failure (p < 0.05). CONCLUSIONS Acute catastrophic failures involved large-magnitude surgical corrections and likely resulted from high mechanical strain on the pelvic instrumentation. Patients with large corrections may benefit from anterior structural support placed at the most caudal motion segment and multiple rods connecting to more than 2 pelvic fixation points. If failure occurs, salvage with a minimum of 4 rods and 4 pelvic fixation points can be successful.
Gastric dysfunction in patients with chronic nausea and vomiting syndromes defined by a noninvasive gastric mapping device
Gharibans, Armen A. , Calder, Stefan , Varghese, Chris , Waite, Stephen , Schamberg, Gabriel , Daker, Charlotte , Du, Peng , Carson, D A, Woodhead, Jonathan S. T., Farrugia, Gianrico , Windsor, John A. , Andrews, Christopher N. , O’Grady, Greg, Alighaleh, Saeed , Carson, Daniel , Farrugia, Gianrico , O'Grady, Gregory , Varghese, Chris , Gharibans, Armen A , Andrews, Christopher N , Schamberg, Gabriel , Daker, Charlotte

Mayo Clinic

Science Translational Medicine | September 21, 2022 | Volume: 14 | Issue: 663 | Pages: No page available

10.1126/scitranslmed.abq3544 | PMID 36130019 Get It

Chronic nausea and vomiting syndromes (NVSs) are prevalent and debilitating disorders. Putative mechanisms include gastric neuromuscular disease and dysregulation of brain-gut interaction, but clinical tests for objectively defining gastric motor function are lacking. A medical device enabling noninvasive body surface gastric mapping (BSGM) was developed and applied to evaluate NVS pathophysiology. BSGM was performed in 43 patients with NVS and 43 matched controls using Gastric Alimetry (Alimetry), a conformable high-resolution array (8 × 8 electrodes; 20-mm interelectrode spacing), wearable reader, and validated symptom-logging app. Continuous measurement encompassed a fasting baseline (30 minutes), 482-kilocalorie meal, and 4-hour postprandial recording, followed by spectral and spatial biomarker analyses. Meal responses were impaired in NVS, with reduced amplitudes compared to controls (median, 23.3 microvolts versus 38.0 microvolts, P < 0.001), impaired fed-fasting power ratios (1.1 versus 1.6, P = 0.02), and disorganized slow waves (spatial frequency stability, 13.6 versus 49.5; P < 0.001). Two distinct NVS subgroups were evident with indistinguishable symptoms (all P > 0.05). Most patients (62%) had normal BSGM studies with increased psychological comorbidities (43.5% versus 7.7%; P = 0.03) and anxiety scores (median, 16.5 versus 13.0; P = 0.035). A smaller subgroup (31%) had markedly abnormal BSGM, with biomarkers correlating with symptoms (nausea, pain, excessive fullness, early satiety, and bloating; all r > 0.35, P < 0.05). Patients with NVS share overlapping symptoms but comprise distinct underlying phenotypes as revealed by a BSGM device. These phenotypes correlate with symptoms, which should inform clinical management and therapeutic trial design.
High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer’s Disease-Causing Mutations
(DIAN), the Dominantly Inherited Alzheimer Consortia, Cilia, Roberto , Sharma, Jennifer , Schneider, Lon S. , Graff‐Radford, Neill R. , Mori, Hiroshi , Nübling, Georg, Andaloussi, Samir EL , Svenningsson, Per , Vöglein, Jonathan , Vöglein, Jonathan , Svenningsson, Per , Sturchio, Andrea , (DIAN), the Dominantly Inherited Alzheimer Consortia, Dwivedi, Alok , Malm, Tarja , Wood, Matthew J. A. , Hill, Emily J. , Nübling, Georg , Ezzat, Kariem , Espay, Alberto J.

Mayo Clinic

Journal of Alzheimer's Disease | September 16, 2022 | Volume: 90 | Issue: 1 | Pages: 333-348

10.3233/jad-220808 | PMID 36120786 Get It

Background: In amyloid-positive individuals at risk for Alzheimer’s disease (AD), high soluble 42-amino acid amyloid-β (Aβ42) levels are associated with normal cognition. It is unknown if this relationship applies longitudinally in a genetic cohort. Objective: To test the hypothesis that high Aβ42 preserves normal cognition in amyloid-positive individuals with Alzheimer’s disease (AD)-causing mutations (APP, PSEN1, or PSEN2) to a greater extent than lower levels of brain amyloid, cerebrospinal fluid (CSF) phosphorylated tau (p-tau), or total tau (t-tau). Methods: Cognitive progression was defined as any increase in Clinical Dementia Rating (CDR = 0, normal cognition; 0.5, very mild dementia; 1, mild dementia) over 3 years. Amyloid-positivity was defined as a standard uptake value ratio (SUVR) ≥1.42 by Pittsburgh compound-B positron emission tomography (PiB-PET). We used modified Poisson regression models to estimate relative risk (RR), adjusted for age at onset, sex, education, APOE4 status, and duration of follow-up. The results were confirmed with multiple sensitivity analyses, including Cox regression. Results: Of 232 mutation carriers, 108 were PiB-PET-positive at baseline, with 43 (39.8%) meeting criteria for progression after 3.3±2.0 years. Soluble Aβ42 levels were higher among CDR non-progressors than CDR progressors. Higher Aβ42 predicted a lower risk of progression (adjusted RR, 0.36; 95% confidence interval [CI], 0.19–0.67; p = 0.002) better than lower SUVR (RR, 0.81; 95% CI, 0.68–0.96; p = 0.018). CSF Aβ42 levels predicting lower risk of progression increased with higher SUVR levels. Conclusion: High CSF Aβ42 levels predict normal cognition in amyloid-positive individuals with AD-causing genetic mutations.
Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
DiIorio, Michael , Kennedy, Kevin , Putman, Michael , Sirotich, Emily , Sattui, Sebastian E. , Foster, Gary , Harrison, Carly , Larché, Maggie , Levine, Mitchell , Moni, Tarin T , Thabane, Lehana , Bhana, Suleman , Costello, Wendy, Grainger, Rebecca , Machado, Pedro , Sufka, Paul , Wallace, Zachary S. , Gore‐Massy, Monique , Kodhek, More A, Lalonde, Nadine, Tomasella, Laura-Ann, Wallace, John, Akpabio, Akpabio , Alpizar-Rodriguez, D. , Berenbaum, Françis , Buliņa, Inita , Chock, Eugenia Yupei , Duff, Eimear , Hsieh, Evelyn , Kibbi, Lina El, Liew, David , Lo, Chieh , Nudel, Michal, Singh, Aman Dev , Hausmann, Jonathan S. , Sparks, Jeffrey A. , Putman, Michael S , Sirotich, Emily , Sattui, Sebastian E , Machado, Pedro M , Robinson, Philip C , Akpabio, Akpabio , Alpízar-Rodríguez, Deshiré , Berenbaum, Francis , Chock, Eugenia Yupei , Liew, David Fl , Singh, Jasvinder A , Ugarte-Gil, Manuel F , Hausmann, Jonathan S , Simard, Julia F , Sparks, Jeffrey A , Grainger, Rebecca , Hsieh, Evelyn , Thabane, Lehana , Kennedy, Kevin , Liew, Jean W. , Robinson, Philip C. , Yazdany, Jinoos , Howard, Richard A, Wallace, John, Beesley, Richard P. , Conway, Richard , Duarte‐García, Alí , Gheita, Tamer A. , Graef, Elizabeth R. , Singh, Jasvinder A. , Singh, Namrata , Ugarte‐Gil, Manuel F.

Mayo Clinic

RMD Open | September 14, 2022 | Volume: 8 | Issue: 2 | Pages: e002587

10.1136/rmdopen-2022-002587 | PMID 36104117 Get It

Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021–15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.
Dynamic Radiographs Are Unreliable to Assess Arthrodesis Following Cervical Fusion: A Modeled Radiostereometric Analysis of Cervical Motion
Pinter, Zachariah W. , Skjaerlund, Jonathan, Michalopoulos, Giorgos D. , Bydon, Mohamad , Sebastian, Arjun S. , Freedman, Brett A. , Nathani, Karim R, Michalopoulos, Giorgos , Nathani, Karim Rizwan , Nassr, Ahmad

Mayo Clinic

Spine | September 9, 2022 | Volume: 48 | Issue: 2 | Pages: 127-136

10.1097/brs.0000000000004470 | PMID 36083848 Get It

Study Design. In vitro study. Objective. The purpose of the present study was to utilize an idealized cervical spine model to determine whether the parallax effect or changes in the position of the spine relative to the x-ray generator influence intervertebral motion parameters on dynamic cervical spine radiographs. Summary of Background Data. The utility of flexion-extension radiographs in clinical practice remains in question due to poor reliability of the parameters utilized to measure motion. Materials and Methods. A cervical spine model with tantalum beads inserted into the tip of each spinous process was utilized to measure interspinous process distance (IPD) on plain radiographs. The model was then manipulated to alter the generator angle and generator distance, and the IPD was measured. The impact of individual and combined changes in these parameters on IPD was assessed. Multivariate analysis was performed to identify independent drivers of variability in IPD measurements. Results. Isolated changes in the generator distance and generator angle and combined changes in these parameters led to significant changes in the measured IPD at each intervertebral level in neutral, flexion, and extension, which, in many instances, exceeded an absolute change of >1 mm or >2 mm. Multivariate analysis revealed that generator distance and generator angle are both independent factors impacting IPD measurements that have an additive effect. Conclusions. In an idealized cervical spine model, small clinically feasible changes in spine position relative to the x-ray generator produced substantial variability in IPD measurements, with absolute changes that often exceeded established cutoffs for determining the presence of pathologic motion across a fused segment. This study further reinforces that motion assessment on dynamic radiographs is not a reliable method for determining the presence of an arthrodesis unless these sources of variability can be consistently eliminated. Level of Evidence. 3